000095456 001__ 95456
000095456 005__ 20230926093530.0
000095456 0247_ $$2doi$$a10.1038/s41929-019-0333-4
000095456 0248_ $$2sideral$$a114071
000095456 037__ $$aART-2019-114071
000095456 041__ $$aeng
000095456 100__ $$0(orcid)0000-0001-8762-5457$$aSancho-Albero, María$$uUniversidad de Zaragoza
000095456 245__ $$aCancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis
000095456 260__ $$c2019
000095456 5060_ $$aAccess copy available to the general public$$fUnrestricted
000095456 5203_ $$aThe transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, Pd catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Here, we have developed a bioartificial device comprising cancer-derived exosomes that are loaded with Pd catalysts by a method that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This hybrid system mediates Pd-triggered dealkylation reactions in vitro and inside cells, and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality; that is, exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the anticancer drug panobinostat.
000095456 536__ $$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 742684-CADENCE$$9info:eu-repo/grantAgreement/EC/H2020/742684/EU/Catalytic Dual-Function Devices Against Cancer/CADENCE$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 658833-ChemoBOOM$$9info:eu-repo/grantAgreement/EC/H2020/658833/EU/Development of Palladium-Labile Prodrugs for Bioorthogonally-Activated Chemotherapy/ChemoBOOM$$9info:eu-repo/grantAgreement/EC/FP7/614715/EU/A Photo-triggered On-demand Drug Delivery System for Chronic Pain/NANOHEDONISM
000095456 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000095456 590__ $$a30.471$$b2019
000095456 591__ $$aCHEMISTRY, PHYSICAL$$b2 / 159 = 0.013$$c2019$$dQ1$$eT1
000095456 592__ $$a11.104$$b2019
000095456 593__ $$aBiochemistry$$c2019$$dQ1
000095456 593__ $$aProcess Chemistry and Technology$$c2019$$dQ1
000095456 593__ $$aCatalysis$$c2019$$dQ1
000095456 593__ $$aBioengineering$$c2019$$dQ1
000095456 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000095456 700__ $$aRubio-Ruiz, Belén
000095456 700__ $$aPérez-López, Ana M.
000095456 700__ $$0(orcid)0000-0002-6873-5244$$aSebastián, Víctor$$uUniversidad de Zaragoza
000095456 700__ $$0(orcid)0000-0003-4160-9720$$aMartín-Duque, Pilar
000095456 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, Manuel$$uUniversidad de Zaragoza
000095456 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaría, Jesús$$uUniversidad de Zaragoza
000095456 700__ $$aUnciti-Broceta, Asier
000095456 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000095456 773__ $$g2, 10 (2019), 864–872$$pNat. catal.$$tNature Catalysis$$x2520-1158
000095456 8564_ $$s1895626$$uhttps://zaguan.unizar.es/record/95456/files/texto_completo.pdf$$yPostprint
000095456 8564_ $$s446758$$uhttps://zaguan.unizar.es/record/95456/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000095456 909CO $$ooai:zaguan.unizar.es:95456$$particulos$$pdriver
000095456 951__ $$a2023-09-26-09:29:49
000095456 980__ $$aARTICLE